Merck (NYSE: MRK ) announced Thursday quarterly earnings rose slightly as that put him in a good momentum for the rest of the year .
The US pharmaceutical giant generated in the first quarter net income to non-GAAP nearly 2.5 billion dollars against 2.4 billion last year around the same time.
This corresponds to earnings per share (EPS) of 89 cents against a consensus was established at 85 cents.
Its revenue declined 1% to $ 9.3 billion, including a negative impact of four percentage points due to currency effects.
In a statement, Merck said to have benefited from its recent product launches.
For 2016, the group continues to expect EPS to GAAP ranging from 1.96 to 2.23 dollars but raised its non-GAAP objectives with EPS now expected between 3.65 and 3.77 dollars.
In pre-market action Merck nibbled 0.7% Thursday.